MicroRNA-21 and multiple myeloma: small molecule and big function

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Multiple myeloma (MM) is a plasma cell malignancy where therapeutic resistance and relapse remain significant challenges.
• MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in cancer pathogenesis.
• MicroRNA-21 (miR-21) is frequently overexpressed in various cancers, including MM.

Purpose of the Study:

• To review the current understanding of microRNA-21's function in multiple myeloma.
• To highlight the significance of miR-21 in MM occurrence, progression, and drug resistance.
• To consolidate findings from laboratory and clinical research on miR-21 in MM.

Main Methods:

• Literature review of studies investigating miR-21 in multiple myeloma.
• Analysis of research focusing on the molecular mechanisms of miR-21 in MM pathogenesis.
• Synthesis of data from preclinical and clinical investigations of miR-21.

Main Results:

• miR-21 is frequently upregulated in multiple myeloma.
• miR-21 contributes to the development, progression, and drug resistance of MM.
• Emerging evidence suggests miR-21's involvement in MM recurrence.

Conclusions:

• MicroRNA-21 is a critical factor in multiple myeloma pathogenesis and therapeutic outcomes.
• Targeting miR-21 may offer novel therapeutic strategies for MM patients.
• Further research into miR-21's role is essential for advancing MM treatment.